(openPR) (Amherst, NH) – As prefilled injection devices continue to replace vials in terms of injections as well as total sector revenue, pharmaceutical and biotech program managers are increasingly integrating syringe and self-injection device technology into their development plans. The result has been a migration toward multi-functional development teams and an increasing reliance on accelerated product feasibility testing. As the factors driving this trend continue to evolve over the next four years, the number of tailored injectable drug products that reach the market will escalate.
The total global market for specialty injectables will exceed one hundred million in 2015, with the majority of growth coming from drug-device combination products. Within the specialty injectables segment, prefilled syringes continue to dominate for anticoagulants such as Lovenox, and for cytokine drug therapies for Hepatitis C, while pen injectors dominate for insulin and hormone replacement, including reproductive hormones and human growth hormone (hGH). A new class of devices – the prefillable safety syringe – is positioned to make serious inroads into both the clinical and self-administration healthcare segments.
Detailed analysis of Specialty Injectable Drugs, therapeutic sectors, and participants is included in a new and comprehensive report. The report documents and analyzes the results of a recent survey of injectable drugs conducted by Greystone Research Associates.
More information is available at
http://www.greystoneassociates.org/Injectable_Delivery.htm
Source: Greystone Research Associates
Presseinformation
Growth of Specialty Injectable Drugs Placing Emphasis on Device Evolution and User Perceptions
Diese Pressemeldung wurde auf openPR veröffentlicht.
Verantwortlich für diese Pressemeldung:Contact:
Mark Smith
Greystone Research Associates
98 Route 101A
Amherst, NH 03031 USA
Voice: 603-595-4340
Fax: 603-218-7020
www.greystoneassociates.org
Mark Smith
Greystone Research Associates
98 Route 101A
Amherst, NH 03031 USA
Voice: 603-595-4340
Fax: 603-218-7020
www.greystoneassociates.org
Über das Unternehmen
About Greystone
Greystone Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis. Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.
Greystone Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis. Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.
Pressebericht „Growth of Specialty Injectable Drugs Placing Emphasis on Device Evolution and User Perceptions“ bearbeiten oder mit dem "Super-PR-Sparpaket" stark hervorheben, zielgerichtet an Journalisten & Top50 Online-Portale verbreiten:
Disclaimer: Für den obigen Pressetext inkl. etwaiger Bilder/ Videos ist ausschließlich der im Text angegebene Kontakt verantwortlich. Der Webseitenanbieter distanziert sich ausdrücklich von den Inhalten Dritter und macht sich diese nicht zu eigen. Wenn Sie die obigen Informationen redaktionell nutzen möchten, so wenden Sie sich bitte an den obigen Pressekontakt. Bei einer Veröffentlichung bitten wir um ein Belegexemplar oder Quellenennung der URL.
Weitere Mitteilungen von Greystone Research Associates
Prefilled Syringes to Reach 4.75 Billion Units in 2016 According to Greystone Research
(Amherst, NH) – Driven by improved device designs, a maturing supply chain infrastructure and broad acceptance of inherent patient and caregiver benefits, prefilled syringes will continue to grow at a double digit rate, climbing to four and three quarter billion units worldwide in 2016, according to the latest estimates from Greystone Research Associates.
Drug developers seeking to package their injectable formulations in prefilled devices need an understanding of the unique technology and business factors defining this sector. The prefille…
Dry Powder Inhalers Continue to Dominate Pipeline Development for Inhaled Systemic Therapeutics
(Amherst, NH) – The search for improved routes of administration for macromolecular therapeutic agents and the desire for noninvasive delivery methods for self-medication of chronic conditions have led to increased interest in pulmonary drug delivery systems. Recent developments, including escalating research activity in powder formulations, advances in particle engineering, and novel device architectures have now positioned dry powder inhalation (DPI) as a formidable challenger to competing pulmonary methods, and are establishing DPI as a si…
Das könnte Sie auch interessieren:
Mit inconso Warehouse Apps mobil auf SAP-Anwendungen zugreifen
… Es fügt sich nahtlos in den Wareneingangsprozess ein und bietet darüber hinaus die Möglichkeit, direkten Kontakt mit dem Lieferanten aufzunehmen. Die „Easy Placing“-App vereinfacht die Warenverräumung. Angereichert mit Artikel- und Platzierungsinformationen weist diese App unkompliziert die Plätze zu, an denen Artikel verräumt werden sollen. inconso …
Emphasis on Reconstituting Drugs at the Point-of-Care Driven by Growth in Lyophilized Drugs
(Amherst, NH) – Unlike oral drugs, a significant number of injectables are supplied in powder form. These drugs have undergone a process called lyophilization, a type of drying process. Drugs in dry form are more stable at room temperature than drugs in solution or suspension.
The number of drugs supplied in lyophilized form has been growing at an increased …
Dry Powder Inhalers Continue to Dominate Pipeline Development for Inhaled Systemic Therapeutics
… as liquids are often shipped frozen to preserve their shelf life and require continuous refrigeration.
As aging population demographics and managed care initiatives drive growth in home health care and self-administration of drug therapies, inhaled medicine is increasingly being viewed as patient-friendly and cost-effective. Our analysis demonstrates …
Refinements in Inhaled Drug Delivery Enhancing Growth Prospects as Global Markets Emerge
… such as menopause, osteoporosis and heart disease, which require long-term therapy, are expected to become significantly more prevalent. This is driving a growing emphasis on drug self-administration for chronic conditions and greater interest in noninvasive drug delivery technology. Because of the patient-friendly nature oral inhalers, inhaled drug …
Prefilled Syringes to Reach 4.75 Billion Units in 2016 According to Greystone Research
… to four and three quarter billion units worldwide in 2016, according to the latest estimates from Greystone Research Associates.
Drug developers seeking to package their injectable formulations in prefilled devices need an understanding of the unique technology and business factors defining this sector. The prefilled syringe ecosystem has evolved to …
Drug of Abuse Testing Market (DOA) Analysis, Development and Demand Forecast to 2020
The worldwide drug of abuse testing market (DOA) is expected to value at $3.9 billion in 2020. Two main drivers leading to growth of drug of abuse market are a significant increase in the use of illicit drugs and rising need for drug testing at organizational level. The market is expected to grow at a CAGR of 5.3% during 2015 to 2020. North America, …
Portable Electronics Providing Opportunities for Specialty Films
… creating opportunities for supply chain participants. The flat screen displays that these devices rely to provide the user with a rewarding experience in turn rely on specialty films to protect the screen and to produce the visual sharpness and rendering that the underlying screen technology enables.
Commercial display screen film applications include …
Innovation drives growth at Evonik
… Chairman
Thomas Wessel
Ute Wolf
Registered Office is Essen
Register Court: Essen Local Court
Commercial Registry B 19474
Company information
Evonik is one of the world leaders in specialty chemicals. The focus on more specialty businesses, customer-orientated innovative prowess and a trustful and performance-oriented corporate culture form the heart …
Dual Chamber Devices for Drug Reconstitution Grow in Response to Ease-of-Use Needs of Self-Medicating Patients
… market penetration, dual chamber injection devices are currently well-represented in seven distinct therapeutic segments. We expect this number to grow as the influence of injectable biologicals on therapeutic practice increases. As biological drugs continue to grow in terms of therapeutics and total prescriptions, the impact of these specialty devices …
Pen Injectors Becoming Commonplace in Self-Administration for Key Chronic Indications
(Amherst, NH) – The evolution in drug injection devices to accommodate new injectable drugs designed for self-administration continues to change the therapeutic drug landscape. Attempting to address key healthcare issues that include patient safety and drug protocol compliance, device designers are now building on the experience of earlier generations …
Sie lesen gerade: Growth of Specialty Injectable Drugs Placing Emphasis on Device Evolution and User Perceptions